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Abstract
Aims-To assess the role of Ki67
immunoreactivity in predicting the clini-
cal progress ofhydatidiform mole.
Methods-Tissue from 87 hydatidiform
moles, 11 normal first trimester placen-
tas, 11 normal term placentas and 17
spontaneous abortions were examined for
expression of Ki67 antigen, using the
monoclonal antibody MIBI.
Results-Ki67 immunoreactivity was
significantly higher in the tissue from
normal first trimester placentas than in
that from normal term placentas and
spontaneous abortions. Among the 87
patients with hydatidiform moles stud-
ied, 20 developed persistent gestational
trophoblastic disease and required subse-
quent treatment. There was no statisti-
cally significant difference in the Ki67
index between the 20 patients who devel-
oped persistent disease and those who did
not.
Conclusion-Hydatidiform moles which
give rise to persistent trophoblastic dis-
ease do not have a higher proliferative
rate than those which do not. The Ki67
index is not useful for predicting the
prognosis ofmolar pregnancies.
(7 Clin Pathol 1994;47:601-604)
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About 8% to 30% of patients with hydatidi-
form mole require chemotherapy after pri-
mary removal due to development of
persistent gestational trophoblastic disease,'
but there seem to be few useful indicators that
can predict such progression. In particular,
histological grading of hydatidiform moles
does not show a correlation with the clinical
outcome.23
It is now widely accepted that tumour cell
kinetics directly influence the clinical course
of patients who have cancer.45 The use of
immunohistochemical methods has become a
popular means of assessing the state of cellu-
lar proliferation in histological material,
because it allows architectural and cytological
features to be preserved and avoids the in vivo
administration of thymidine analogues.6
The diagnostic and prognostic value of
Ki67 immunostaining in tumours has been
well documented,67 but the drawback in the
use of this antibody is that its application is
restricted to fresh material as the epitope does
not survive routine histopathological fixation
in formaldehyde or alcohol. Recently, mono-
clonal antibodies against recombinant parts of
the Ki67 antigen, designated MIB1 to 3, have
been raised.8 The immunostaining pattern as
well as the morphological and cell cycle distri-
bution of MIB1 expression is identical with
that of Ki67 and so can be regarded as a
true Ki67 equivalent.89 Using a modified
microwave oven pretreatment of the paraffin
wax sections, it was possible to detect the
antigen previously defined by Ki67 in rou-
tinely formalin fixed and paraffin wax embed-
ded tissues.5 6
Studies on the status of cell proliferation in
hydatidiform mole have been scanty. Our pre-
vious study on the expression of proliferating
cell nuclear antigen (PCNA) in human tro-
phoblastic disease using the monoclonal anti-
body PC 10 showed that the PCNA index was
not useful for predicting the progression of
molar pregnancies to persistent trophoblastic
diseases.'0 As an extension of that work, the
present study assesses the prognostic value of
Ki67 index using the recently available mono-
clonal antibody MIBi.
Methods
The pathology reports of patients with a
diagnosis of complete or partial hydatidiform
moles treated at the Queen Mary Hospital,
University of Hong Kong, were reviewed.
Eighty seven cases, including 39 partial mole
and 48 complete mole, treated between
January 1989 and December 1990, with
available blocks were retrieved. The histo-
logical features of these cases were assessed
using generally agreed and accepted diagnos-
tic criteria." 12 Tissues from 11 cases of first
trimester induced abortion, 11 full term
placentas, and 17 cases of spontaneous abor-
tions were also included for the study. Three
of the 17 cases of spontaneous abortion show
microscopic hydropic changes.
The tissues included uterine curettings and
blocks from hysterectomy specimens all of
which were routinely fixed in 10% formalin
and embedded in paraffin wax. Sections 4 jim
thick were cut and mounted on gelatin coated
glass slides and dried overnight in an oven at
37°C. The sections were dewaxed in xylene
and rehydrated through graded concentra-
tions of alcohol. Endogenous peroxidase was
blocked using 3% H202 in methanol. After
pretreatment with 0-5% trypsin-calcium chlo-
ride (pH = 7-8) the sections were immersed in
10 mM (pH = 6) sodium citrate buffer in a
thermoresistant plastic box and were
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processed in a microwave oven for five min-
utes at 700W. The sections were then cooled
in phosphate buffered saline before being
immunostained. Immunohistochemisty was
performed using the avidin-biotin complex
immunoperoxidase method (Dakopatts UK).
A monoclonal mouse antibody MIB 1
(Immunotech SA, France) was applied at a 1
in 100 dilution and incubations were per-
formed overnight at 4°C. Biotinylated sheep
anti-mouse antibody was used as the linker
molecule and diaminobenzidine-hydrogen
peroxide was used as chromogen. A light
haematoxylin counterstain was used. Sections
were dehydrated in alcohol, cleared in xylene,
and mounted.
Sections were examined at high power
(x 400) and 20 fields per section were chosen
at random. The spatial distribution of positive
staining in the sections was assessed. A
quantitative estimate of nuclear labelling
index for MIBI immunoreactivity (Ki67)
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Figure 1 Immunoreactivityfor Ki67 is confined to the nuclei of the cytotrophoblasts in
both (A) complete and (B) partial hydatidiform moles; the syncytiotrophoblasts are
negative. The positive and negative nuclei are indicated by arrows and arrowheads,
respectively.
index was made by scoring positive
nuclei/total number of counted nuclei in a
minimum of 1000 trophoblastic cells in each
case. Decidua, myometrium, fetal tissue and
other tissues found in the sections were
excluded from the analysis. The nuclei were
scored as positive or negative without regard
to staining intensity.
To ensure consistency of MIB1 staining
between batches tissue from a colonic
carcinoma was used as a known positive
control in each batch. The experiment was
repeated if there was any apparent fluctuation
in the Ki67 index of this control. Negative
controls were included by substituting TRIS-
buffered saline for the primary antibody.
Trypsin and microwave pre-treatments were
confirmed to be necessary in the preliminary
study.
All the patients with partial or complete
moles in this study were followed up with a
review of clinical records. Persistent gesta-
tional trophoblastic disease was diagnosed if
there was a plateau in fl-human chorionic
gonadotrophin values for four weeks, or if
there was (hCG) renewed increased in values
for three consecutive weeks when pregnancy
was excluded.'3 These patients were then
evaluated for further treatment with
chemotherapy. Seven patients with partial
mole and 13 patients with complete mole had
persistently raised hCG values four weeks
after giving birth and were diagnosed as
having persistent gestational trophoblastic
disease. Single or multiple agents were given
depending on the risk scores of the patients.
Statistical analysis of the Ki67 index was
performed using the Mann-Whitney U test.
Results
MIB1 staining was confined to the nuclei of
cytotrophoblast cells in the normal first
trimester and term placentas, spontaneous
abortions, partial and complete moles; the
syncytiotrophoblasts, amniotic epithelium,
and endothelial cells were unreactive to MIB1
(figs 1A and B). Occasional weak nuclear
staining for MIB 1 was also noted in the
stromal cells. The mitotic figures were particu-
larly immunoreactive and were highlighted by
MIB 1 (fig 2). In a given section there was also
some regional variation in staining of tro-
phoblast cells.
The results tabulated in tables 1 and 2
show a wide range of variation in the Ki67
index in each group of patients. The differ-
ences in counts between normal first trimester
and term placentas (p = 0.0001), as well as
those between normal first trimester placentas
and spontaneous abortions (p = 0-0009) were
significant (table 1). Twenty out of the 87
cases of hydatidiform moles subsequently
developed persistent gestational trophoblastic
disease and required chemotherapy. The
Ki67 index of those 20 patients who devel-
oped persistent disease was not significantly
different (p > 0-05) from that of the 67
patients who had spontaneous remission of
the disease (table 2).
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Figure 2 The mitotic figure is highlighted by the antibody MIBL.
Discussion
Many studies have searched for variab]
would allow the clinical progress of a h
iform mole to be predicted. Historicalli
ine size larger than expected for gesi
dates or greater than 20 weeks' size,b.
ovarian enlargement (theca-lutein
patient's age over 40, and uterinebM
after evacuation of the fetus have been
ated with higher risk of persistenttrophe
disease.alo tHowever, the introduct
accurate radioimmunoassay methods ft
surement of hGG has revolutionalis
mode of management of hydatidiform
In effect, the hCG regression patter r
the most specific prognostic indicatora
been adopted by most gynaecologin
management of hydatidiform
Nevertheless, the potential risk of F
defaulting follow up always exists a
exploration for an alternative prognost
cator continues.
Immunohistochemical determinati
cell proliferation associated antiger
aroused the interest of histopatholog
recent years. One of the most wide]
reagents in this field is the antibody
This reacts with a nuclear non-histone
of 395 and 345 kilodaltons present
active parts of the cell cycle-that is,
G2, and mitosis-but is absent in GO.17 18 This
antibody has been used in a large number of
studies of cell proliferation in human tissues
with the aim of providing prognostic informa-
tion in a range of tumour types.' 6 7 19 Of par-
ticular note is that expression occurs during
GI, increases during the cell cycle, and then
rapidly declines after mitosis.'520 Other
immunohistochemical proliferation markers,
such as proliferation cell nuclear antigen
(PCNA), are expressed in non-cycling cells-
for example in association with DNA repair,
so that they tend to persist after the end of
mitosis. It is easier, then, to overestimate the
degree of proliferative activity in a tissue, due
to retention of staining in postmitotic cells.2'
Immunoreactivity for MIB 1 in normal pla-
centas, hydropic abortions, and hydatidiform
moles was largely confined to cytotrophoblasts.
This pattern confirms previous studies which
have identified the cytotrophoblast as the
active germinative zone, based on results
obtained by autoradiography, total organ
DNA analysis, flow cytometry, morphometric
les that analysis and studies on proliferating cell
.ydatid- nuclear antigen.'o 22-26
y, uter- The results (table 1) show a wide range of
tational variation in the Ki67 index obtained from
filateral each group of placental tissue. Such variation
cysts), may be related to technical factors such as the
leeding time of fixation, because the tissues used in
associ- this study were archival material with no stan-
oblastic dardised fixation time. Alternatively, this
ion of range of Ki67 index may also reflect an intrin-
)r mea- sic variation in the proliferative potential of
,ed the the cytotrophoblast in different cases of each
mole.'6 category of tissue. Moreover, variation of
*emains staining was observed in different regions of
and has the same section suggesting a lack of syn-
ists for chrony in the proliferation of cytotrophoblast
mole. within the same placenta.
,atients There was a significant difference between
nd the the Ki67 indexes of the first trimester and
ic indi- term placentas. This supports the previous
findings that there was very active growth of
ion of the trophoblast in the first trimester placentas,
ns has and such villous trophoblast growth is much
gists in diminished in term placenta.23 27 Thus Ki67
ly used expression seems to have a logical correlation
7 Ki67. with the proliferative activity in normal pla-
protein centas. The Ki67 index in hydropic abortion,
in all although lower than that for normal first
G1, S, trimester placentas, was much higher than
Table Ki67 index (per 1000 cels) in normalfirst trimester and term placentas andfirst timester spontaneous
abortions
Number Mean Median Standard deviation Range
Normal first trimester placentas 11 314-3 312-0 98-2 194-496
Term placentas 11 23-4 21-0 17-4 1- 61
First trimester spontaneous abortions 17 150-4 139-0 128-4 11-504
Table 2 Comparison ofKi67 index (per 1000 cells) in tissue from hydatidiform moles with or without development of
persistent gestational trophoblastic disease
Hydatidiform moles Number Mean Median Standard deviation Range
With persistent trophoblastic disease 20 370-8 414-5 142-1 85-563
Spontaneous remission with no persistent 67 297-3 296 158-2 13-629
trophoblastic disease
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that of term placenta. These findings are simi-
lar to that found in a study comparing the
PCNA immunoreactivity of hydropic abor-
tions and first trimester placentas.2' This has
been explained by the possibility that after
fetal death the trophoblast is still viable and
continues to function at a diminished level.
The frequency with which persistent tro-
phoblastic disease occurs after a molar gesta-
tion is dependent on the sensitivity of the
follow up hCG assay, length of follow up, type
of primary treatment, and terminology used in
reporting sequelae.2529 Studies have shown
that 8%-30% of patients with hydatidiform
mole will require treatment some time after
primary evacuation of the fetus.' The wide
range in the percentage of patients treated
reflects the different criteria used by various
investigators as to what constitutes persistent
disease. In this study, using our usual criteria
for persistent gestational trophoblastic dis-
ease,"3 17-9% (7/39) of partial moles and 27%
(13/48) of complete moles subsequently
required treatment. These figures, though
within the range reported, were higher than
the expected local figures of 11 3% for partial
mole and 17-8% for complete mole as found
in previous study."3 The discrepancy is proba-
bly due to selection of cases because only
cases with available paraffin wax blocks were
included in this study. More objective assess-
ment of clinical outcome, such as documenta-
tion of subsequent development of metastasis
may be used in future studies on prognostic
factors in gestational trophoblastic disease.
Most studies have found that histopatho-
logical grading of hydatidiform mole, includ-
ing morphometric assessment of trophoblastic
hyperplasia, has little predictive value for
prognosis.2' Our previous study on PCNA
also showed that PCNA could not predict the
progression of molar pregnancies to persistent
trophoblastic disease.
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